BACKGROUND: Urinary neutrophil gelatinase-associated lipocalin (uNGAL) is expressed by kidney tubules that are acutely damaged, but few studies have investigated the association of neutrophil gelatinase-associated lipocalin (NGAL) with different forms of chronic kidney disease (CKD). HIV-associated nephropathy (HIVAN) is a progressive form of CKD characterized by collapsing focal segmental glomerulosclerosis and microcytic tubular dilatation that typically leads to end-stage renal disease (ESRD). METHODS: Previously, we reported that microcystic tubular dilatations specifically expressed NGAL RNA, implying that the detection of uNGAL protein could mark advanced HIVAN. To test this idea, we performed a comparative study of diverse proteinuric glomerulopathies in 25 patients who were HIV positive. RESULTS: Eighteen patients had HIVAN and seven had other glomerulopathies (four membranoproliferative glomerulonephritis, one membranous glomerulonephritis, one amyloid and one malarial GN). HIVAN and non-HIVAN patients did not differ with respect to age, ethnicity, serum creatinine, estimated GFR, proteinuria or the prevalence of hypocomplementemia (6 versus 29%, P = 0.18), but HIVAN patients were less likely to have HCV infections. HIVAN patients expressed 4-fold higher levels of uNGAL than the patients with other glomerulopathies [387 ± 338 versus 94 ± 101 μg/g urine creatinine (uCr), P = 0.02]. A cutpoint of 121.5 μg uNGAL/g uCr demonstrated 94% sensitivity and 71% specificity for the diagnosis of HIVAN, with an area under the receiver operator characteristic curve of 0.88. CONCLUSION: In summary, while HIVAN disease is currently diagnosed only by kidney biopsy, uNGAL can distinguish HIVAN from other proteinuric glomerulopathies in the HIV-infected patient, likely because of its specific expression from characteristic microcysts.
BACKGROUND: Urinary neutrophil gelatinase-associated lipocalin (uNGAL) is expressed by kidney tubules that are acutely damaged, but few studies have investigated the association of neutrophil gelatinase-associated lipocalin (NGAL) with different forms of chronic kidney disease (CKD). HIV-associated nephropathy (HIVAN) is a progressive form of CKD characterized by collapsing focal segmental glomerulosclerosis and microcytic tubular dilatation that typically leads to end-stage renal disease (ESRD). METHODS: Previously, we reported that microcystic tubular dilatations specifically expressed NGAL RNA, implying that the detection of uNGAL protein could mark advanced HIVAN. To test this idea, we performed a comparative study of diverse proteinuric glomerulopathies in 25 patients who were HIV positive. RESULTS: Eighteen patients had HIVAN and seven had other glomerulopathies (four membranoproliferative glomerulonephritis, one membranous glomerulonephritis, one amyloid and one malarial GN). HIVAN and non-HIVAN patients did not differ with respect to age, ethnicity, serum creatinine, estimated GFR, proteinuria or the prevalence of hypocomplementemia (6 versus 29%, P = 0.18), but HIVAN patients were less likely to have HCV infections. HIVAN patients expressed 4-fold higher levels of uNGAL than the patients with other glomerulopathies [387 ± 338 versus 94 ± 101 μg/g urine creatinine (uCr), P = 0.02]. A cutpoint of 121.5 μg uNGAL/g uCr demonstrated 94% sensitivity and 71% specificity for the diagnosis of HIVAN, with an area under the receiver operator characteristic curve of 0.88. CONCLUSION: In summary, while HIVAN disease is currently diagnosed only by kidney biopsy, uNGAL can distinguish HIVAN from other proteinuric glomerulopathies in the HIV-infectedpatient, likely because of its specific expression from characteristic microcysts.
Authors: Daniele Marras; Leslie A Bruggeman; Feng Gao; Nozomu Tanji; Mahesh M Mansukhani; Andrea Cara; Michael D Ross; G Luca Gusella; Gary Benson; Vivette D D'Agati; Beatrice H Hahn; Mary E Klotman; Paul E Klotman Journal: Nat Med Date: 2002-05 Impact factor: 53.440
Authors: Lynda Anne Szczech; Samir K Gupta; Ramez Habash; Antonio Guasch; Robert Kalayjian; Richard Appel; Timothy A Fields; Laura P Svetkey; Katherine H Flanagan; Paul E Klotman; Jonathan A Winston Journal: Kidney Int Date: 2004-09 Impact factor: 10.612
Authors: Andrew M Hall; Simon G Edwards; Marta Lapsley; John O Connolly; Kreesan Chetty; Stephen O'Farrell; Robert J Unwin; Ian G Williams Journal: Am J Kidney Dis Date: 2009-09-23 Impact factor: 8.860
Authors: Neal Paragas; Thomas L Nickolas; Christina Wyatt; Catherine S Forster; Meghan Sise; Susan Morgello; Bernd Jagla; Charles Buchen; Peter Stella; Simone Sanna-Cherchi; Maria Luisa Carnevali; Silvia Mattei; Achiropita Bovino; Lucia Argentiero; Andrea Magnano; Prasad Devarajan; Kai M Schmidt-Ott; Landino Allegri; Paul Klotman; Vivette D'Agati; Ali G Gharavi; Jonathan Barasch Journal: J Am Soc Nephrol Date: 2009-07-23 Impact factor: 10.121
Authors: Wenjun Ju; Felix Eichinger; Markus Bitzer; Jun Oh; Shannon McWeeney; Celine C Berthier; Kerby Shedden; Clemens D Cohen; Anna Henger; Stefanie Krick; Jeffrey B Kopp; Christian J Stoeckert; Steven Dikman; Bernd Schröppel; David B Thomas; Detlef Schlondorff; Matthias Kretzler; Erwin P Böttinger Journal: Am J Pathol Date: 2009-06 Impact factor: 4.307
Authors: Jose M Miro; Federico Cofan; Joan C Trullas; Christian Manzardo; Carlos Cervera; Montserrat Tuset; Federico Oppenheimer; Mercedes Brunet; Asuncion Moreno; Josep M Campistol; Jose M Gatell Journal: Curr HIV/AIDS Rep Date: 2012-09 Impact factor: 5.071
Authors: Sofia Perazzo; Ángel A Soler-García; Yetrib Hathout; Jharna R Das; Patricio E Ray Journal: Proteomics Clin Appl Date: 2015-06 Impact factor: 3.494
Authors: Vasantha Jotwani; Rebecca Scherzer; Alison Abraham; Michelle M Estrella; Michael Bennett; Prasad Devarajan; Kathryn Anastos; Mardge H Cohen; Marek Nowicki; Anjali Sharma; Mary Young; Phyllis C Tien; Carl Grunfeld; Chirag R Parikh; Michael G Shlipak Journal: Antivir Ther Date: 2013-08-23
Authors: Lucy J Campbell; Tracy Dew; Rashim Salota; Emily Cheserem; Lisa Hamzah; Fowzia Ibrahim; Pantelis A Sarafidis; Caje F Moniz; Bruce M Hendry; Mary Poulton; Roy A Sherwood; Frank A Post Journal: BMC Nephrol Date: 2012-08-10 Impact factor: 2.388